Bacterial over-expression of functionally active human CT2 (SLC22A16) carnitine transporter

Michele Galluccio1 · Tiziano Mazza1 · Mariafrancesca Scalise1 · Maria Chiara Sarubbi1 · Cesare Indiveri1,2*

Received: 11 November 2021 / Accepted: 20 April 2022 / Published online: 24 May 2022
© The Author(s), under exclusive licence to Springer Nature B.V. 2022

Abstract

Background Escherichia coli is a widely used tool for the over-expression of human proteins for studying structure and function. The toxicity of human proteins for E. coli often hampers the expression. This study aims to find conditions for the expression of a membrane transporter known as the carnitine transporter CT2. The knowledge on this transporter is scarce, thus obtaining the recombinant protein is very important for further studies.

Methods and Results The cDNAs coding for human CT2 (hCT2) was cloned in the pH6EX3 vector and different transformed E. coli strains were cultured in absence or in presence of glucose. hCT2 expression was obtained. The protein was purified and reconstituted into proteoliposomes in a functionally active state.

Conclusions Using the appropriate IPTG concentration, together with the addition of glucose, hCT2 has been expressed in E. coli. The protein is active and shows capacity to transport carnitine in proteoliposomes. The results have a great interest in basic biochemistry of membrane transporters and applications to human health since hCT2 is involved in human pathology.

Keywords Carnitine · SLC · Protein expression · CT2 · Liposome · Purification

Introduction

Carnitine is a vitamin-like molecule involved in the transport of long-chain fatty acids from the cytosol to the mitochondria, where they are metabolized through β-oxidation [1]. In humans, the mitochondrial transport of carnitine derivatives is mediated by the carnitine/acylcarnitine translocase (SLC25A20) [2], whereas the absorption, re-adsorption and tissue distribution occur via some members of the SLC22 family [3, 4], among which, the members number 5 (SLC22A5) and 16 (SLC22A16) are those mainly responsible for carnitine traffic in human body. In particular, SLC22A5, known as OCTN2, is an high affinity transporter for carnitine, thus playing a pivotal role in the carnitine homeostasis maintenance, being mainly localized at the intestinal and renal epithelia [5]. The SLC22A16, known as CT2, FLIPT2, or OCT6, is described as a carnitine transporter with a peculiar tissue distribution; indeed, the protein is particularly expressed in the bone marrow, in testis, where it is involved in the maturation of human spermatozoa [6], in hematopoietic tissues, including CD34+ and leukemia cells [7], and in endometrium where its expression is regulated by progesterone [8]. The studies on SLC22A5 are at a more advanced stage of investigation, whereas, the knowledge on SLC22A16 is still at infancy. As a carnitine transporter, SLC22A16 is involved in the regulation of fatty acid oxidation (FAO), which plays an important role also in the metabolic transformation of cancer cells [9]. In particular, AML (Acute Myeloid Leukemia) cells strongly depends on mitochondrial metabolism and FAO and present a specific up-regulation of the SLC22A16 carnitine transporter which can be exploited as a pharmacological target [10]. Indeed, SLC22A16 inhibition reduced the growth/viability and cell cycle progression of AML cells and enhanced the cytotoxic effect of chemotherapeutic agents, including daunorubicin, cytarabine, tigecycline or etomoxir [10]. Due to its involvement not only in carnitine traffic, but also in drugs absorption in healthy and cancer cells, SLC22A16 can be
considered as a multirole transporter [11], in line with the main features of the SLC22 family members. As an example, the SLC22A16 over-expression in different cancer cell lines [12, 13], drove the characterization of SLC22A16 as a doxorubicin importer. Therefore, several studies aimed to investigate the effect of SLC22A16 genotype on doxorubicin pharmacology. In particular, the SLC22A16 T1226C was associated with a greater incidence of “doxorubicin dose delay” and leucopenia but had no impact on survival on 230 patients recruited at Newcastle Tyne Hospitals NHS Foundation Trust [14], whereas the c.146A > G variant may influence the pharmacokinetics of doxorubicin and doxorubicinol in Asian breast cancer patients [15], and rs12210538 A/G may increase the probability of 3/4 febrile neutropenia in Iranian breast cancer patients [16]. Moreover, SLC22A16 mediates cisplatin uptake in lung cancer cells [17], and high-affinity uptake of the anticancer polyamine analog bleomycin-A5 in colorectal cancer cells [18]. In this scenario, the availability of the recombinant human SLC22A16 transporter may have a great relevance for performing structure/function relationships studies as well as applications to human health, allowing directly testing interaction of candidate drugs with the transporter. We report the successful over-expression of the recombinant human SLC22A16 using a strategy based on appropriate modulation of inducer concentrations, growth temperature, and glucose supply to bacterial cells. Interestingly, the over-expressed protein was obtained in a functionally active form, that opens important perspectives for addressing the above-described purposes.

Materials and methods

Chemicals used for experiments, protease inhibitor cocktail (P8849), Nickel Affinity Gel (HIS-Select® P6611) and the Monoclonal Anti-polyHistidine-Peroxidase antibody (A7058) were from Sigma–Aldrich; pCOLD I plasmid from Takara; unstained protein molecular weight marker, restriction endonucleases and specific reagents for cloning from Thermo scientific; E. coli RosettaGami2 strain from Novagen; BL21 codon plus RIL and Lemo21 from Agilent Technologies; codon optimized hCT2 sequence was from Genscript. t-[3H]-Carnitine from ARC (America Radiolabeled Chemicals), C12E8 from TCI Europe, Amberlite XAD-4, egg yolk phospholipids, Sephadex G-75, t-carnitine from Sigma-Aldrich, TGX Stain-Free Kit from Bio-Rad.

Cloning of hCT2

The cDNA encoding for human CT2 transporter (SLC22A16) (UniProtKB: Q86VW1; GenPept accession no. NP_149116.2), was codon optimized according to the E. coli codon usage by Genscript. The 1734 bp cDNA corresponding to the hCT2 encoding sequence was then sub-cloned, between Bam HI and Sal I restriction sites into the pH6EX3 or pCOLD I expression vector. The resulting recombinant plasmids, defined as pH6EX3-hCT2 and pCOLD I-hCT2, encode a 6His-tagged fusion protein corresponding to the hCT2 carrying the extra N-terminal MSPIHHHHHHLVPRGS or MNHKVHHHHHHIEGRH-MELGTEGS sequence, respectively.

Expression of hCT2 transporter

To produce the 6His-hCT2 recombinant protein, E. coli BL21 codon plus cells, were transformed with the pH6EX3-hCT2 or pCOLD I-hCT2 construct. Selection of transformed colonies was performed on LB-agar plates added with 100 µg/mL ampicillin and 34 µg/mL chloramphenicol. Different media (LB or TY 2X at pH 7.0) prepared in absence or in presence of different glucose concentrations were assayed. According to the number of conditions to be tested, colonies were inoculated in a different volume of a specific medium and cultured overnight at 37 °C under rotary shaking (160 rpm). The day after, the culture was diluted 1:20 in fresh medium added with the specific antibiotics and specifically treated, according to the used construct. In the case of pCOLDI-hCT2 construct, when the optical density measured at 600 nm wavelength was 0.8–1, the cultures were shocked on ice for 10 min (under manual agitation every 1 min), then incubated for 40 min at 15 °C under rotary shaking (160 rpm). Different IPTG concentrations (from 0.05 to 0.4 mM) were tested to induce protein expression with the exception of one aliquot, grown in absence of inducer, (negative control). The cultures were continued for up to 24 h at 15 °C at 160 rpm. Every 2 h, aliquots were collected and centrifuged at 3000xg, and at 4 °C for 10 min; the pellets were stored at –20 °C. A bacterial pellet aliquot, after thawing, was dissolved in a resuspension buffer (20 mM Hapes/Tris, 300 mM NaCl pH 7.5) added with protease inhibitor cocktail according to manufacturer instructions. The bacterial suspensions were sonified in an ice bath for 10 min (pulse of 1 s on, and 1 s off) at 40 Watt, using a Vibracell VCX-130 sonifier. The insoluble cell fractions were analyzed by SDS-PAGE and western blotting. In the case of pH6EX3-hCT2 construct, after overnight growth at 37 °C, when the optical density of the bacterial culture measured at 600 nm wavelength was 0.8–1, the growth temperature was lowered to 28 °C and different IPTG concentrations (from 0.05 to 0.4 mM) were tested to induce protein expression with the exception of one aliquot, grown in absence of inducer, (negative control). The induced cultures and the control were kept at 28 °C under rotary shaking for up to 8 h. Every 2 h, aliquots were collected and treated as described above. For large scale
experiments, a 50 mL inoculation was diluted to 1 L of fresh broth added with specific antibiotics. The bacterial pellet was dissolved in 48 mL of resuspension buffer and sonified as described above.

**Purification of the hCT2 protein**

ÅKTA start FPLC equipment was used for purification. In order to purify 6His- hCT2 protein, 500 mL of cell culture were centrifuged, and the pellet resuspended in 24 mL of resuspension buffer (20 mM Hepes/Tris, 300 mM NaCl pH 7.5). The bacterial suspension containing the hCT2 protein was washed with 0.1 M Tris/HCl pH 8.0, and centrifuged at 12,000×g for 10 min. The new pellet was solubilized adding 400 µL of 8 M urea, 100 µL of 100 mM DTE, 54 µL of 10% sarkosyl, and 546 µL of a renaturing buffer (A) containing: 0.1% sarkosyl, 200 mM NaCl, 10% glycerol, and 20 mM Tris/HCl at pH 8.0. After centrifugation (12,000×g, 10 min, 4 °C), the supernatant was added to a His Trap HP column (5 mL Ni Sepharose) pre-equilibrated with a buffer containing 20 mM Tris HCl pH 8.0, 10% glycerol, 200 mM NaCl, and 0.1% sarkosyl (10 mL). The column was washed with a washing buffer containing 20 mM Tris HCl pH 8.0, 10% glycerol, 200 mM NaCl, 0.1% C12E8, and 5 mM DTE (10 mL). The elution of the protein was triggered by a linear imidazole gradient 0–240 mM. Unspecifically bound proteins were eluted at 140 mM imidazole. Purified hCT2 protein was collected in 2.5 mL of the fractions containing 240 mM imidazole. The fractions were pulled together and passed through a PD-10 column for removing imidazole using a buffer composed by 0.3% C12E8, 200 mM NaCl, 10% glycerol, 5 mM DTE, 20 mM Tris/HCl at pH 8. The protein was then used for reconstitution in proteoliposomes as described in the following paragraph.

**Reconstitution of the hCT2 into liposomes**

The purified hCT2 was reconstituted by removing the detergent from mixed micelles containing detergent, protein and phospholipids by incubation with 0.5 g Amberlite XAD-4 resin under rotatory stirring (1200 rpm) at 23 °C for 60 min, using a procedure previously described [19]. The composition of the initial mixture used for reconstitution was: 350 µL of the purified protein (9 µg protein in desalting buffer), 70 µL of 10% C12E8, 100 µL of 10% egg yolk phospholipids in the form of sonicated liposomes prepared as previously described [20] and 20 mM Tris/HCl pH 7.5 in a final volume of 700 µL. The final protein/lipid ratio was 1/1100 (w/w). This ratio is in the range of that frequently used for reconstitution of membrane transporters into proteoliposomes [20–23].

**Transport measurements**

To remove the external compounds, 600 µL of proteoliposomes were passed through a Sephadex G-75 column (0.7 cm diameter x 15 cm height) pre-equilibrated with 10 mM Tris/HCl pH 7.5. From these columns, 550 µL of proteoliposomes were collected and divided into aliquots (samples) of 100 µL. Transport was started by adding 50 µM of [3H]-carnitine to the proteoliposome samples, as indicated in the figure legends. In control samples, transport in empty liposomes, i.e., without incorporated protein, is measured. The effect of internal carnitine or external sodium on [3H]-carnitine transport reaction was evaluated by adding 10 mM carnitine to the reconstitution mixture or by adding 50 mM Na-Gluconate along with [3H]-carnitine in the transport tube. The assay temperature was 25 °C. Transport was stopped by passing 100 µL of each sample through a Sephadex G-75 column (0.6 cm diameter x 8 cm height) in order to separate the external from the internal radioactivity. Samples were eluted with 1 mL 50 mM NaCl and collected in 3 mL of scintillation mixture, vortexed and counted. The experimental values were corrected by subtracting the respective control to obtain specific radioactivity expressed as nmol/min mg/protein. Kinetic analysis was performed at 15 min, i.e., in the linear range of time courses. Experimental data were plotted using the Grafit (version 5.0.13) software using first order rate, Lineweaver–Burk equations. Results were expressed as means ± SD.

**Data analysis**

Results are expressed as means ± SD. GraFit 5.0.13 software was used to calculate kinetic parameters. Comparisons between two groups were performed with the two tailed Student’s unpaired t test. For multiple comparisons, one-way ANOVA followed by Tukey’s post hoc test was employed.

**Protein quantification**

Protein concentration was measured by the method of Lowry, modified for the presence of detergents [24]. Proteins were separated by SDS–PAGE on 12% polyacrylamide gels performed according to Laemmli [25], using the Hoefer SE260 mini-vertical unit and stained by Coomassie-brilliant blue or using a stain-free technology (Bio-Rad). Quantitative evaluation of Coomassie-stained or stain-free visualized protein bands was carried out using the Chemidoc imaging system equipped with Quantity One software (Bio-Rad).

**Western blot assay**

hCT2 was immuno-detected using the Monoclonal Anti-polyHistidine-Peroxidase antibody 1:10,000.
Results and discussion

Over-expression of hCT2

In order to obtain expression of CT2, the hCT2-pH6EX3 or hCT2-pCOLD I construct was firstly used for transforming E. coli BL21 codon plus strain adopted to overcome codon bias. A single colony was inoculated from each different plate and cultured overnight in an appropriate volume of LB broth. After 12–16 h, a 1:10 dilution in fresh LB was performed and the growth was monitored. During the exponential phase of growth (OD ~ 0.8), the cultures containing the different constructs were differently treated as described in materials and methods section. Then, the IPTG concentration was modulated in a range of 0.05–0.4 mM to find the best compromise between optimal rate of protein synthesis and lowest toxic effects on bacteria. The production of the protein as function of time was then monitored in the case of transformation with hCT2-pH6EX3. Following IPTG addition, an OD reduction was observed in any condition with the maximum effect at the highest IPTG concentration tested (Fig. 1), highlighting a putative toxic effect of the protein on cell growth, as previously observed for other proteins [26]. Whereas, in the case of pCOLD I, the cells were harvested at a single time since growth was performed at low temperature, as suggested for this specific plasmid, leading to a very slow rate of growth in all conditions. The production of the protein, verified by western blotting analysis (Fig. 2a), was strongly influenced by the plasmid type indicating the pH6EX3 as the preferred plasmid (Fig. 2a lanes 1–6) with respect to pCOLD I (Fig. 2a, lanes 7–9). For the hCT2-pH6EX3 construct, the protein synthesis increased up to 8 h (Fig. 2a, lanes 4–6) and was inversely proportional to the inducer concentration. This phenomenon, previously described in the case of other transporters [26], is in agreement with the toxicity of the protein of interest towards bacterial cells. Thus, the lower IPTG concentration resulting in a slower rate of protein production has the effects of decreasing the toxic effect. Surprisingly, the use of codon optimized construct did not improve the production of the protein of interest in these cells (not shown). Probably, the human tRNAs present in BL21 codon plus E. coli strain was enough to overcome the codon bias. Moreover, we also tested the possible effect of codon optimized construct transforming another E. coli strain, i.e., Lemo21 which does not carry human tRNAs, without any significant improvement (Fig. 2b). We could not well explain this phenomenon that might also be related with the relatively low rate of synthesis of the protein of interest. To further decrease the toxic effects due to a possible leakage expression of the protein of interest, the effect of glucose in the growth medium was tested. BL21 codon plus E. coli strain was transformed with hCT2-pH6EX3 construct and cultured as described above in absence or in presence of two different glucose concentrations (0.5% or 1%). The production of hCT2 increased with the increase of glucose concentration, being about four times higher in the presence of 1% glucose (Fig. 2c lane 5) than in the absence of glucose (Fig. 2c lane 1). Also in these conditions, the amount of over-expressed protein was inversely proportional to the inducer concentration.

Purification of over-expressed hCT2

Starting from the insoluble fraction of BL21 cell lysate obtained in optimal conditions, i.e., 8 h of induction with 0.05 mM IPTG in presence of 1% glucose at 28 °C, the purification of hCT2 protein was attempted under denaturing conditions followed by an on-column refolding procedure, as previously described for other SLC transporters [20, 26] with substantial modifications. For refolding, the strong detergent sarkosyl was substituted by octaethylene glycol monododecyl ether (C12E8). The binding of hCT2 to the resin was effective, as no reactivity against anti-His antibody was observed in the corresponding pass-through or wash fractions (Fig. 3c lanes 7 and 8, respectively). Then, a 0–240 mM imidazole gradient was performed. Unspecifically bound proteins were eluted up to 140 mM imidazole (Fig. 3b, lane 3), purified hCT2 was eluted at 240 mM imidazole (Fig. 3b, lane 4) with a yield of 0.17 mg/L of cell culture and reconstituted in proteoliposomes (Fig. 3b lane 5). The purified and reconstituted hCT2 proteins were identified by western blotting (Fig. 3c, lanes 9 and 10, respectively).
Fig. 2 hCT2 expression in BL21 codon plus E. coli strain. a E. coli BL21 codon plus strain was transformed with codon optimized hCT2-pH6EX3 (lanes 1–6) or hCT2-pCOLD I (lanes 7–9) construct. The protein synthesis was induced for 6 (lanes 1–3), 8 (lanes 4–6) or 22 h (lanes 7–9) in presence of 0.05 mM (lanes 1, 4, 7), 0.1 mM (lanes 2, 5, 8), or 1 mM IPTG (lanes 3, 6, 9). 35 μg (total proteins) of the insoluble fractions of induced cell lysates were analyzed by western blotting analysis. b E. coli Lemo21 strain was transformed with hCT2-pH6EX3 (lane 1) or with codon optimized hCT2-pH6EX3 (lane 2). The protein synthesis was induced for 8 h in presence of 0.05 mM IPTG. 35 μg (total proteins) of the insoluble fractions of induced cell lysates were analyzed by western blotting analysis. c BL21 codon plus E. coli strain was transformed with hCT2-pH6EX3. The protein synthesis was induced for 8 h in the absence (positive control) or in the presence of different glucose and IPTG concentrations (lanes 2–7). 35 μg (total proteins) of the insoluble fractions of induced cell lysates were analyzed by western blotting analysis. Lane 1: pellet of the cell lysate induced (as in a lane 4) with 0.05 mM IPTG for 8 h in absence of glucose. Lanes 2–4: pellet of the cell lysate induced for 8 h in the presence of 0.5% glucose and 0.05, 0.1 and 0.4 mM IPTG, respectively. Lanes 5–7: pellet of the cell lysate induced for 8 h in the presence of 1% glucose and 0.05, 0.1 and 0.4 mM IPTG, respectively. 35 μg (total proteins) were loaded in each lane.
The amount of refolded protein (inserted in the proteoliposome membrane) in an active state accounted for 0.085 mg/L of cell culture. A similar evaluation was previously performed for a different transporter [27].

Reconstitution of hCT2 in proteoliposomes and transport assay

To evaluate the hCT2 functionality and to perform a first biochemical characterization, the purified hCT2 was reconstituted in proteoliposomes and transport was assayed as described in materials and methods section. The reconstitution was carried out mimicking the procedure previously described for OCTN2 [28] due to the similarity of the substrate hypothetically transported by hCT2 and to the inclusion of hCT2 in the same cluster of OCTN-related proteins, as recently reported [29]. Indeed, using this strategy a hCT2-mediated carnitine transport could be detected in proteoliposomes, as function of time (Fig. 4). The hCT2 ability in mediating carnitine uptake was demonstrated by the much higher amount of taken up carnitine by proteoliposomes harboring the reconstituted hCT2 with respect to the diffusion observed in empty liposomes, i.e., liposomes without incorporated hCT2 (Fig. 4a). The hCT2 mediated transport, obtained by subtracting the controls from empty liposomes (Fig. 4b), followed a first order equation typical of a protein-mediated process with a calculated initial rate of 0.011 ± 0.0022 nmol/mg/min. Furthermore, the carnitine transport increased as a function of the protein amount incorporated into proteoliposomes, by an almost linear dependence (Fig. 4c). The transport reaction was unidirectional and sodium independent, as observed in Fig. 5a and in line with previously described data [6]. Finally, the dependence of the transport rate on carnitine concentration was studied (Fig. 5b). Data were fitted in a Michaelis–Menten equation of enzyme kinetics, that can be applied to transport processes as well [30], and a $k_m$ of 288 ± 125 µM and a $V_{max}$ of 0.14 ± 0.03 nmol/mg/min were derived.

Conclusions

The described results represent, to our knowledge, the first report of heterologous expression of the human hCT2 in bacteria. This is the basis for performing characterization of this transporter that belongs to a SLC family whose structural characterization is still in nuce. Moreover, the over-expressed hCT2 is functionally active; this achievement, even though still preliminary, is a milestone for further structure/function relationships studies of this scarcely known transporter, that is most probably involved in crucial cell functions and is also linked to common human pathologies.
**Fig. 4** [3H]-carnitine Uptake in proteoliposomes. In a, hCT2 was purified and reconstituted in proteoliposomes as described in materials and methods. Transport was started by adding 50 µM [3H]-carnitine to proteoliposomes (filled circle) or control liposomes i.e., liposomes without incorporated protein (open circle). In b, net protein mediated specific transport, obtained by subtracting uptake in control liposomes from uptake in proteoliposomes from Fig. 4a. Data were plotted according to first order rate equation. In c, Dependence of transport on amount of reconstituted hCT2 in proteoliposomes. Transport was started by adding 50 µM [3H]-carnitine and stopped after 60 min. All results are means±SD from three independent experiments. In c, multiple comparisons were performed using one-way ANOVA test followed by Tukey’s test, p-value less than 0.01 was calculated. NS indicate non-significant difference between pair of groups estimated by Tukey’s test.

**Fig. 5** Functional and kinetic characterization of hCT2 reconstituted in proteoliposomes. hCT2 was purified and reconstituted in proteoliposomes as described in materials and methods. In a, effect of external sodium and internal carnitine on [3H]-carnitine uptake in proteoliposomes. Transport was started by adding 50 µM [3H]-carnitine and stopped after 60 min. Results are means±SD from three independent experiments. No significant difference from the control was observed as estimated by Student’s t-test (P < 0.05). In b, kinetics of hCT2 reconstituted in proteoliposomes. Transport was measured in 15 min as uptake in proteoliposomes of [3H]-carnitine at the indicated concentrations, as described in materials and methods. Data was analyzed according to Michaelis–Menten equation as transport rate versus [3H]-carnitine concentration. Results are means±SD from three independent experiments.
Acknowledgements We are grateful to Dr. Konstantinos Beis (Imperial College London) for supervising Tiziano Mazza during part of his PhD program.

Funding This work was supported by “SLIFIPACRO. DE—Sviluppo e industrializzazione farmaci innovativi per terapia molecolare personalizzata PA.CRO. DE.” Grant No. PON ARS01_00568 to CI granted by MIUR (Ministry of Education, University and Research) Italy.

Declarations

Conflict of interest All authors declare no conflict of interest.

Ethical approval This article does not contain any studies with human participants or animals performed by any of the authors.

References

1. Bieber LL (1988) Carnitine. Annu Rev Biochem 57:261–283. https://doi.org/10.1146/annurev.bi.57.070188.001401
2. Huizing M, Iacobazzi V, Ijlst L, Savelkoul P, Ruitenbeek W, van den Heuvel L, Indiveri C, Smeitink J, Tijbels F, Wanders R, Palmieri F (1997) Cloning of the human carnitine-acylcarnitine carrier cDNA and identification of the molecular defect in a patient. Am J Hum Genet 61(6):1239–1245. https://doi.org/10.1086/301628
3. Pochini L, Scalise M, Galluccio M, Indiveri C (2013) OCTN1: a small transporter subfamily with great relevance to human pathophysiology, drug discovery, and pharmaceutical implications. Pharm Res 24(7):1227–1251. https://doi.org/10.1007/s11095-010-9254-2
4. KoepSELL H, Lips K, Volk C (2007) Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharmacol Rev 59(1):1277–1251. https://doi.org/10.1177/1538455006293930
5. Pochini L, Galluccio M, Scalise M, Console L, Indiveri C (2019) OCTN: a small transporter subfamily with great relevance to human pathophysiology, drug discovery, and diagnostics. SLAS Discov 24(2):89–110. https://doi.org/10.1177/2472755218781281
6. Enomoto A, Wempe MF, Tsuchida H, Shin HJ, Cha SH, Anzai N, Goto A, Sakamoto A, Niwa T, Kanai Y, Anders MW, Endou H (2002) Molecular identification of a novel organic cation transporter specific to human testis. Insights into the mechanism of carnitine accumulation. J Biol Chem 277(39):36262–36271. https://doi.org/10.1074/jbc.M203883200
7. Gong S, Lu X, Xu Y, Swiderski CF, Jordan CT, Moscow JA (2002) Identification of OCT6 as a novel organic cation transporter preferentially expressed in hematopoietic cells and leukemias. Exp Hematol 30(10):1162–1169. https://doi.org/10.1016/s0301-472x(02)00901-3
8. Sato N, Ito K, Onogawa T, Akahira J, Unno M, Abe T, Niikura H, Yaegashi N (2007) Expression of organic cation transporter SLC22A16 in human endometria. Int J Gynecol Pathol 26(1):53–60. https://doi.org/10.1097/01.pgp.0000225845.67245.b3
9. Carracedo A, Cantley LC, Pandolfi PP (2013) Cancer metabolism: fatty acid oxidation in the limelight. Nat Rev Cancer 13(4):227–232. https://doi.org/10.1038/nrc3483
10. Wu Y, Hurren R, MacLean N, Gronda M, Jitkova Y, Sukhai MA, Minden MD, Schimmel AD (2015) Carnitine transporter CT2 (SLC22A16) is over-expressed in acute myeloid leukemia (AML) and target knockdown reduces growth and viability of AML cells. Apoptosis 20(8):1099–1108. https://doi.org/10.1007/s10495-015-1137-x
11. Zhao W, Wang Y, Yue X (2018) SLC22A16 upregulation is an independent unfavorable prognostic indicator in gastric cancer. Future Oncol 14(21):2139–2148. https://doi.org/10.2217/fon-2018-0207
12. Okabe M, Unno M, Harigae H, Kaku M, Okitu Y, Sasaki T, Mizoi T, Shiiba K, Takenaga H, Terasaki T, Matsuno S, Sasaki I, Ito S, Abe T (2005) Characterization of the organic cation transporter SLC22A16: a doxorubicin importer. Biochem Biophys Res Commun 333(3):754–762. https://doi.org/10.1016/j.bbrc.2005.05.174
13. Novak AJ, Asmann YW, Maurer MJ, Wang C, Slager SL, Hodge LS, Manske M, Price-Troska T, Yang ZZ, Zimmermann MT, Nowakowski GS, Ansell SM, Witzig TE, McPhail E, Ketterling R, Feldman AL, Dogan A, Link BK, Habermann TM, Cerhan JR (2015) Whole-exome analysis reveals novel somatic genomic alterations associated with outcome in immunomodulation-treated diffuse large B-cell lymphoma. Blood Cancer J 5:e346. https://doi.org/10.1038/bcj.2015.69
14. Bray J, Sludden J, Griffin MJ, Cole M, Verrill M, Jamieson D, Boddy AV (2010) Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide. Br J Cancer 102(6):1003–1009. https://doi.org/10.1038/sj.bjc.6605587
15. Lal S, Wong ZJ, Jada SR, Xiang X, Chen SH, Ang PC, Figg WD, Lee EJ, Chowbay B (2007) Novel SLC22A16 polymorphisms and influence on doxorubicin pharmacokinetics in Asian breast cancer patients. Pharmacogenomics 8(6):567–575. https://doi.org/10.1080/14622416.2006.10863016
16. Faraji A, DehghanManshadi HR, Mobarak M, Zare M, Houshmard M (2016) Association of ABCB1 and SLC22A16 gene polymorphisms with incidence of doxorubicin-induced febrile neutropenia: a survey of Iranian breast cancer patients. PLoS ONE 11(12):e0168519. https://doi.org/10.1371/journal.pone.0168519
17. Kunii E, Oguri T, Kasai D, Otsa H, Uemura T, Takakuwa O, Ohkubo H, Takemura M, Maeno K, Niimi A (2015) Organic cation transporter OCT6 mediates cisplatin uptake and resistance to cisplatin in lung cancer. Cancer Chemother Pharmacol 75(5):985–991. https://doi.org/10.1007/s00280-015-0723-x
18. Aouida M, Poulin R, Kamotar D (2010) The human carnitine transporter SLC22A16 mediates high affinity uptake of the anticancer polyamine analogue bleomycin-A5. J Biol Chem 285(9):6275–6284. https://doi.org/10.1074/jbc.M109.046151
19. Scalise M, Console L, Galluccio M, Pochini L, Indiveri C (2020) Chemical targeting of membrane transporters: insights into structure/function relationships. ACS Omega 5(5):36262–36271. https://doi.org/10.1021/acs. omega.9b04078
20. Cosco J, Scalise M, Colas C, Galluccio M, Martini R, Rovella F, Mazza T, Ecker GF, Indiveri C (2020) ATP modulates SLC7A5 coupled aspartate transport catalyzed by GltTk. Commun Biol 3(1):69104
21. Bamber L, Harding M, Monne M, Slotboom DJ, Kunji ER (2007) The yeast mitochondrial ADP/ATP carrier preferentially expressed in hematopoietic cells and leukemias. Exp Hematol 35(10):1162–1169. https://doi.org/10.1016/s0301-472x(02)00901-3
22. Trinco G, Arkhipova V, Garaeva AA, Hutter CA, Seeger MA, Guskov A, Slotboom DJ (2021) Kinetic mechanism of Na+(+)/coupled aspartate transport catalyzed by GltTk. Commun Biol 4(1):751. https://doi.org/10.1038/s42003-021-02267-y
23. Szymatowicz I, Stanek WK, Majsnerowska M, Swier L, Pardon E, Babicka M, M的日i M, Majoza D, Nowakowski GS, Ansell SM, Witzig TE, McPhail E, Ketterling R, Feldman AL, Dogan A, Link BK, Habermann TM, Cerhan JR (2015) Whole-exome analysis reveals novel somatic genomic alterations associated with outcome in immunomodulation-treated diffuse large B-cell lymphoma. Blood Cancer J 5:e346. https://doi.org/10.1038/bcj.2015.69
24. Dulley JR, Grieve PA (1975) A simple technique for eliminating interference by detergents in the lowry method of protein determination. Anal Biochem 64(1):136–141. https://doi.org/10.1016/0003-2697(75)90415-7
25. Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227(5259):680–685. https://doi.org/10.1038/227680a0
26. Galluccio M, Pantanella M, Giudice D, Brescia S, Indiveri C (2020) Low temperature bacterial expression of the neutral amino acid transporters SLC1A5 (ASCT2), and SLC6A19 (BOAT1). Mol Biol Rep. https://doi.org/10.1007/s11033-020-05717-8
27. Holzhuter K, Geertsma ER (2022) Uniport, not proton-symport, in a non-mammalian SLC23 transporter. J Mol Biol 434(2):167393. https://doi.org/10.1016/j.jmb.2021.167393
28. Zhang L, Gui T, Console L, Scalise M, Indiveri C, Hauserl S, Kullak-Ublick GA, Gai Z, Visentin M (2021) Cholesterol stimulates the cellular uptake of L-carnitine by the carnitine/organic cation transporter novel 2 (OCTN2). J Biol Chem 296:100204. https://doi.org/10.1074/jbc.RA120.015175
29. Console L, Scalise M, Mazza T, Pochini L, Galluccio M, Giangregorio N, Tonazzi A, Indiveri C (2020) Carnitine traffic in cells. Link with cancer. Front Cell Dev Biol 8:583850. https://doi.org/10.3389/fcell.2020.583850
30. Scalise M, Pochini L, Giangregorio N, Tonazzi A, Indiveri C (2013) Proteoliposomes as tool for assaying membrane transporter functions and interactions with xenobiotics. Pharmaceutics 5(3):472–497. https://doi.org/10.3390/pharmaceutics5030472

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.